The PD-L1 Biomarker Testing Market offers opportunities driven by the rising incidence of non-small cell lung cancer and the ...

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...

NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP) in collaboration with the International Association for the Study of Lung Cancer (IASLC), Pulmonary Pathology Society (PPS ...

Jonathan Thompson, MD, MS, emphasized that comprehensive biomarker testing with next-generation sequencing and PD-L1 analysis—implemented as reflex testing at biopsy—is essential to guide precision ...

A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract PD-L1 biomarker details from an electronic health record (EHR). PD-L1 ...

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...

GUILDFORD, UK / ACCESSWIRE / November 9, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in ...